228 related articles for article (PubMed ID: 31901479)
1. Emerging biomarkers in Multiple Myeloma: A review.
Gupta N; Sharma A; Sharma A
Clin Chim Acta; 2020 Apr; 503():45-53. PubMed ID: 31901479
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of circulatory microRNA-203 in serum as novel potential diagnostic marker for multiple myeloma.
Gupta N; Kumar R; Seth T; Garg B; Sati HC; Sharma A
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1601-1611. PubMed ID: 30891618
[TBL] [Abstract][Full Text] [Related]
3. Human Plasma Extracellular Vesicle Isolation and Proteomic Characterization for the Optimization of Liquid Biopsy in Multiple Myeloma.
Reale A; Khong T; Xu R; Chen M; Mithraprabhu S; Bingham N; Spencer A; Greening DW
Methods Mol Biol; 2021; 2261():151-191. PubMed ID: 33420989
[TBL] [Abstract][Full Text] [Related]
4. Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis.
Soliman AM; Das S; Teoh SL
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299097
[TBL] [Abstract][Full Text] [Related]
5. The role of circulating miRNAs in multiple myeloma.
Zhang J; Xiao X; Liu J
Sci China Life Sci; 2015 Dec; 58(12):1262-9. PubMed ID: 26607481
[TBL] [Abstract][Full Text] [Related]
6. Liquid biopsies for multiple myeloma in a time of precision medicine.
Ferreira B; Caetano J; Barahona F; Lopes R; Carneiro E; Costa-Silva B; João C
J Mol Med (Berl); 2020 Apr; 98(4):513-525. PubMed ID: 32246161
[TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNA CCAT2 as a potential serum biomarker for diagnosis and prognosis of multiple myeloma.
Xu H; Yin Q; Shen X; Ju S
Ann Hematol; 2020 Sep; 99(9):2159-2171. PubMed ID: 32591878
[TBL] [Abstract][Full Text] [Related]
8. [Circulating Serum MicroRNA as Diagnostic Biomarkers for Multiple Myeloma].
Xu YN; Xiao CR; Huang YD; Lu QY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):471-475. PubMed ID: 28446295
[TBL] [Abstract][Full Text] [Related]
9. Expression of Peripheral Blood miRNA-720 and miRNA-1246 Can Be Used as a Predictor for Outcome in Multiple Myeloma Patients.
Ren Y; Li X; Wang W; He W; Wang J; Wang Y
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17(7):415-423. PubMed ID: 28601493
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive biomarker developments in multiple myeloma.
Wallington-Beddoe CT; Mynott RL
J Hematol Oncol; 2021 Sep; 14(1):151. PubMed ID: 34556161
[TBL] [Abstract][Full Text] [Related]
11. Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review).
Finotti A; Allegretti M; Gasparello J; Giacomini P; Spandidos DA; Spoto G; Gambari R
Int J Oncol; 2018 Oct; 53(4):1395-1434. PubMed ID: 30085333
[TBL] [Abstract][Full Text] [Related]
12. The potential diagnostic power of CD138+ microparticles from the plasma analysis for multiple myeloma clinical monitoring.
Liu ZY; Tian MY; Deng L; Wang YS; Xing R; Liu H; Fu R
Hematol Oncol; 2019 Oct; 37(4):401-408. PubMed ID: 31291481
[TBL] [Abstract][Full Text] [Related]
13. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.
Besse L; Sedlarikova L; Kryukov F; Nekvindova J; Radova L; Slaby O; Kuglik P; Almasi M; Penka M; Krejci M; Adam Z; Pour L; Sevcikova S; Hajek R
PLoS One; 2015; 10(9):e0137294. PubMed ID: 26389804
[TBL] [Abstract][Full Text] [Related]
14. [Classification, staging and prognostic indices for multiple myeloma].
Hotta T
Nihon Rinsho; 2007 Dec; 65(12):2161-6. PubMed ID: 18069256
[TBL] [Abstract][Full Text] [Related]
15. Syndecan-1 in multiple myeloma: relationship to conventional prognostic factors.
Aref S; Goda T; El-Sherbiny M
Hematology; 2003 Aug; 8(4):221-8. PubMed ID: 12911939
[TBL] [Abstract][Full Text] [Related]
16. Serum DKK1 is correlated with γ peak of serum electrophoresis in multiple myeloma: a multicenter biomarker study.
Hashemi ZS; Khalili S; Malaei F; Mard-Soltani M; Jafarisani M; Lotfi J; Deemeh MR; Zakeri A; Rasaee MJ
Biomark Med; 2019 Oct; 13(15):1297-1306. PubMed ID: 31596134
[No Abstract] [Full Text] [Related]
17. A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma.
Muz B; de la Puente P; Azab F; Luderer MJ; King J; Vij R; Azab AK
Br J Haematol; 2016 Apr; 173(1):70-81. PubMed ID: 26729247
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
Waldschmidt JM; Anand P; Knoechel B; Lohr JG
Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
[TBL] [Abstract][Full Text] [Related]
19. Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids.
Okajima W; Komatsu S; Ichikawa D; Miyamae M; Ohashi T; Imamura T; Kiuchi J; Nishibeppu K; Arita T; Konishi H; Shiozaki A; Morimura R; Ikoma H; Okamoto K; Otsuji E
World J Gastroenterol; 2017 Aug; 23(31):5650-5668. PubMed ID: 28883691
[TBL] [Abstract][Full Text] [Related]
20. An update on extracellular vesicles in multiple myeloma: a focus on their role in cell-to-cell cross-talk and as potential liquid biopsy biomarkers.
De Luca L; Laurenzana I; Trino S; Lamorte D; Caivano A; Musto P
Expert Rev Mol Diagn; 2019 Mar; 19(3):249-258. PubMed ID: 30782029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
